New IP combined with VERAXA’s deep ADC and antibody expertise to give rise to new therapeutic strategies with unique safety features
The addition of a clinical-stage FLT3-targeting cancer antibody program acts as steppingstone for further pipeline and technology expansion.
The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.